Melanotan-2

Melanotan-2 is a synthetic analog of alpha-melanocyte-stimulating hormone. It is supplied in lyophilized vials commonly rated at 10 mg in the research market and is typically logged on a daily cadence during loading phases and less frequently during maintenance phases.

Melanotan-2 is a synthetic peptide analog of the body's native alpha-melanocyte-stimulating hormone (α-MSH). Its development originated from research conducted at the University of Arizona in the 1980s by a team of scientists including Mac E. Hadley and Victor J. Hruby. The primary research goal was to design a molecule that mimicked the function of α-MSH but possessed significantly greater stability and potency. The native α-MSH is a linear peptide that is subject to rapid enzymatic degradation in the body, giving it a very short biological half-life of only a few minutes. This inherent instability made it impractical for studies where sustained melanocortin receptor activation was desired, prompting the development of more durable analogs.

The key structural innovation of Melanotan-2 is its cyclization, which distinguishes it from the linear α-MSH. It is a small cyclic heptapeptide with the amino acid sequence cyclo[Asp-His-D-Phe-Arg-Trp-Lys]. This circular structure is formed by a lactam bridge between the aspartic acid and lysine residues. This modification makes the peptide conformationally constrained and far more resistant to the peptidases that would normally cleave the linear peptide chain. The result is a molecule with a dramatically extended biological half-life, allowing for a much longer duration of action after administration and enabling studies on the effects of sustained melanocortin system activation.

Melanotan-2 binds to multiple melanocortin receptors. Personal logs pair the dose history with whatever the protocol targets — pigmentation notes, response ratings, or general wellbeing tracking.

The mechanism of Melanotan-2 is characterized by its action as a non-selective agonist for a range of melanocortin receptors (MCRs). The melanocortin system is comprised of five distinct G-protein coupled receptors, labeled MC1R through MC5R, which are distributed differently throughout the body and mediate different physiological processes. While native α-MSH also interacts with several of these receptors, Melanotan-2 binds with high affinity to MC1R, MC3R, MC4R, and MC5R. This lack of selectivity is a defining feature and is responsible for the broad spectrum of effects observed in research and documented in personal-tracking logs.

The multi-receptor binding profile of Melanotan-2 is what distinguishes it from other melanocortin peptides like Melanotan-1 and bremelanotide (PT-141). MC1R is most famously studied for its role in regulating skin pigmentation and inflammation. MC3R and MC4R are heavily concentrated in the central nervous system and are subjects of intense study regarding their roles in energy homeostasis, appetite regulation, and sexual function. MC5R is studied for its function in regulating exocrine gland secretion. Because Melanotan-2 interacts with this entire suite of receptors, its observed response profile is more complex and wide-ranging than that of a more selective agonist.

Loading-phase protocols are typically daily; maintenance-phase protocols are less frequent. Recording the transition from loading to maintenance explicitly in the log is what makes the phase change auditable later.

A common protocol structure documented in personal logs for Melanotan-2 involves two distinct phases: a 'loading' phase and a 'maintenance' phase. The initial loading phase typically consists of small, frequently administered doses. Users may plan to schedule these administrations daily or every other day over a period of 7 to 21 days. The objective from a data-logging perspective is not simply to document the passage of time, but to track the cumulative dose required to reach a specific, observable endpoint. Meticulously recording each administration during this period allows for a granular analysis of the dose-response relationship unique to the individual.

Upon reaching the desired response level, users typically transition to a maintenance phase. This involves adjusting the schedule to a less frequent cadence, such as once or twice per week, to sustain the observed state. The dose amount may also be adjusted during this phase. Logging the specific date of this transition is one of the most critical data entry points for any long-term tracking plan. This marker allows calculation tools to properly attribute dosage and observations to either the initial accumulation period or the subsequent sustainment period, providing a clear and auditable record for personal review.

The illustrative example on this page assumes a 10 mg vial reconstituted with 2 mL of bacteriostatic water — concentration of 5 mg per mL. A 0.5 mg illustrative dose is 0.1 mL or 10 units on a U-100 syringe.

Many users prefer 3 or 4 mL of diluent on a 10 mg vial to produce cleaner per-dose unit counts. The calculator handles any combination.

The small dose magnitudes often documented during a Melanotan-2 loading phase introduce a potential for measurement imprecision. For example, if a 10 mg vial is reconstituted with 2 mL of diluent to yield a standard concentration of 5 mg/mL, a typical loading dose of 0.25 mg would be only 0.05 mL, or 5 units on a U-100 insulin syringe. An even smaller dose of 0.1 mg would equate to just 0.02 mL, or a scant 2 units. Such small volumes are at the lower boundary of what can be accurately and consistently drawn with standard syringes, increasing the risk of measurement error and impacting the integrity of dose-tracking data.

To address this measurement challenge, a frequent workflow adjustment involves reconstituting the peptide with a greater volume of diluent to decrease its final concentration. For instance, reconstituting the same 10 mg vial with 4 mL of diluent would produce a concentration of 2.5 mg/mL. At this lower concentration, a 0.25 mg dose now corresponds to a much more manageable 0.1 mL, or 10 units on a U-100 syringe. This greater volume is easier to see and measure accurately, reducing the margin of error. It is vital to document the exact diluent volume used so that all dose calculations accurately reflect the intended milligram amount.

Lyophilized Melanotan-2 powder is typically stored refrigerated until reconstitution. The in-use reconstituted vial is kept refrigerated and used within several weeks.

The phase transition from loading to maintenance is the easiest thing to lose track of without a structured log. Recording the date of the transition is what makes the timeline reconstructible later.

For this peptide, the most impactful data to track is the cumulative dose during the loading phase. The response curve is often closely tied not to any single administration but to the total amount of the peptide introduced over the entire initial period. An effective log should therefore calculate and display a running total of the cumulative milligrams administered from the start date. By correlating this cumulative figure with dated observations, a user can monitor the relationship between the total exposure and the observed outcome, which is a core purpose of systematic personal tracking.

In addition to quantitative data like dose and volume, a comprehensive log for Melanotan-2 should include fields for qualitative, subjective observations. Research links certain melanocortin receptors (MC3R, MC4R) to phenomena such as appetite modulation, transient facial flushing, and nausea. Scheduling and documenting the timing and intensity of such observations alongside the dosage data provides a richer dataset. This allows the user to later analyze potential correlations between dose timing, cumulative dose, and the presence or absence of these subjectively observed responses, creating a more complete personal record.